is farxiga a glp 1 agonist SGLT2 vs GLP-1 for CKD: Which Better? AZ's GLP-1 Bydureon and SGLT2
Description
On average, GLP-1 use leads to a modest amount of weight loss, averaging between 5-10% of body weight, while some users may not experience any weight changes
CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients
Higher doses of GLP-1R agonists can achieve clinically relevant weight loss, and greater increases in dose levels, in theory, can drive more weight-lowering efficacy
The lower total cost is mainly attributable to the reduced costs for emergency visits and inpatient admissions in the GLP-1RA group
